e13037#Background:Pertuzumab, Docetaxel and Trastuzumab (PTH) regimen constitutes one of the standard treatment regimens in human epidermal growth factor receptor-2 (HER2) positive metastatic breast cancer (MBC). The real-world outcomes of its use from the Indian sub-continent are lacking.Methods:...
trastuzumab and pertuzumab, they're already at steady state with their dosing regimen and so when you switch them over to subcutaneous trastuzumab and pertuzumab, generally for their convenience, you don't need a loading dose of the trastuzumab and pertuzumab. You just give the maintenance dosi...
A UK cancer centre set out to switch all patients currently receiving IV infusion of pertuzumab and trastuzumab over to the combined SC injection in a safe and timely manner and to initiate all future patients on the combined SC injection. MATERIALS AND METHODS: Organisational governance approval ...
Among 130 (72.6%) patients who received carboplatin plus taxane in combination with pertuzumab and trastuzumab (TCbHP), carboplatin was removed from the regimen of six patients due to intolerable AEs. Therefore, only 124 (69.3%) patients completed the TCbHP regimen. Forty-six patients (25.7%) re...
Pertuzumab with trastuzumab plus docetaxel was effective in reducing the brain metastases from breast cancer. Further studies are warranted to confirm the effect of this regimen on brain metastases. 展开 关键词: Breast Brain metastasis Pertuzumab Radiation Surgery ...
Neoadjuvant and adjuvant pertuzumab plus trastuzumab with docetaxel continued to show improvements in event-free survival, disease-free survival and overall survival vs trastuzumab/docetaxel and placebo in Asian patients with HER2-positive early or local
The PATRICIA study (NCT02536339) examined the efficacy and safety of pertuzumab plus high-dose trastuzumab in patients with HER2-positive metastatic breast cancer (MBC) with progressive central nervous system (CNS) metastases following radiotherapy. Prim
Frontline pertuzumab plus trastuzumab and docetaxel improved survival by nearly 16 months in metastatic HER2-positive breast cancer, according to results from the phase III CLEOPATRA study that are now published in The New England Journal of Medicine.
The PATRICIA study (NCT02536339) examined the efficacy and safety of pertuzumab plus high-dose trastuzumab in patients with HER2-positive metastatic breast cancer (MBC) with progressive central nervous system (CNS) metastases following radiotherapy. Prim
Our analysis shows a significant improvement in overall survival with pertuzumab, trastuzumab, and docetaxel in patients with HER2-positive metastatic breast cancer, compared with placebo, trastuzumab, and docetaxel. Since this effect was not achieved at the expense of adverse events, this regimen repre...